

RESEARCH NOTE

Open Access



# Epigenetic mechanisms shape the underlining expression regulatory mechanisms of the STAT3 in multiple sclerosis disease

Arezoo Hosseini<sup>1,2,3,4</sup>, Zohreh Babaloo<sup>2,3</sup>, Tohid Gharibi<sup>1,2,3,4</sup>, Navid Shomali<sup>1,2,3,4</sup>, Farooq Marofi<sup>3</sup>, Vida Hashemi<sup>6</sup>, Hormoz Ayromlou<sup>5</sup>, Milad Asadi<sup>2</sup>, Shima Rahmani<sup>2</sup>, Saeed Noorolyai<sup>2</sup>, Dariush Shanehbandi<sup>2</sup> and Behzad Baradaran<sup>2,3\*</sup>

## Abstract

**Objectives:** Immunological tolerance is mediated by CD4<sup>+</sup>CD25<sup>+</sup> regulatory T (Treg) cells. Studies have shown that thymic and peripheral generations of Treg cells depend on the CD28 signaling pathway. T helper 17 (Th17) cells are involved in the pathophysiology of various inflammatory diseases. Cytokines, such as interleukin (IL)-6 and TGF- $\beta$ , regulate the reciprocal development of Th17 and Treg cells. In CD4<sup>+</sup> T cells, signal transducer and activator of transcription 3 (STAT3) play a critical role in the induction of Th17 cell differentiation and inhibition of Treg cell development.

**Results:** In this study, we investigated the STAT3 methylation and gene expression status in patients with MS. Our study demonstrated that the level of STAT3 methylation decreased in relapsing–remitting MS patient compared to control groups, which the decreases were statistically significant. STAT3 gene expression increased in patient group relative to healthy one, and the increases were found to be statistically significant. According to our findings, it can be suggested that DNA hypermethylation of STAT3 affects the gene expression. In addition, there is a strong and significant negative correlation between the methylation status and mRNA level of STAT3.

**Keywords:** STAT3, Multiple sclerosis, Methylation, Iran

## Introduction

Multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system (CNS), has been evidenced to cause demyelination and axonal degeneration within the brain and spinal cord [1, 2]. The exact etiopathology of MS has not yet been clarified, but most studies have recognized MS as an autoimmune disease mediated by autoreactive CD4<sup>+</sup> T cells [3].

Immunological tolerance is a critical factor in the prevention of chronic infection, cancer, and autoimmune diseases [4]. Central tolerance operates in the thymus where autoreactive T cells with high affinity for self-antigens are negatively deleted [5]. Given that not all antigens are present in the thymus, self-reactive T cells can enter the peripheral blood [5]. Therefore, central tolerance alone is insufficient, and peripheral tolerance mechanisms are required [6]. CD4<sup>+</sup>CD25<sup>+</sup> regulatory T (Treg) cells are major suppressor T lymphocytes and mediate peripheral tolerance [7, 8]. Forkhead box P3 (FOXP3) transcription factor is also necessary for the differentiation of Treg cells [9, 10]. Although Treg cells differentiate naturally in the thymus, these cells can also be generated

\*Correspondence: baradaranb@tbzmed.ac.ir

<sup>2</sup> Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Full list of author information is available at the end of the article



from CD4<sup>+</sup>CD25<sup>+</sup> naive T cells into adaptive Tregs in the periphery [11–13]. Adaptive Treg cells can be induced in the periphery when encountered with repeated antigens [14].

Researchers have suggested that the CD28/B7 costimulatory molecule is essential for the expression of CD25 and FOXP3 on Tregs [15–17]. It has also been indicated that in the absence of the CD28 costimulatory pathway, the peripheral number of Tregs decreases [16]. Besides, Lck-binding motif in the cytosolic tail of CD28 is required for Tregs generation [18]. However, it is uncertain how CD28 leads to the FOXP3 expression and Treg development [16]. Treg cells are involved in maintaining anergic state and exert suppressive function in various inflammation and autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and MS [17, 19–21].

In MS patients, autoreactive CD4<sup>+</sup> T cells display mainly T helper 17 (Th17) phenotype [3]. Cytokines, such as TGF-β and interleukin (IL)-6, play a key role in regulating Th17 cell differentiation [3, 22]. Retinoic acid receptor-related orphan receptor (ROR) γt transcription factor induces the differentiation of naive CD4<sup>+</sup> T cells into Th17 cells [22, 23], which are pathogenic in MS due to the production of cytokines such as IL-17, IL-21, and IL-22 [24]. In MS, IL-17 leads to blood–brain barrier disruption and clinical disease activity and symptoms [25]. The upregulation of RORγt is dependent on STAT3 [26]. Following the binding of IL-6 to IL-6R, STAT3 is phosphorylated on Tyr<sup>705</sup>, dimerizes, moves into the nucleus and regulates the gene expression [27, 28]. STAT3 functions distinctly in the Th17 development and regulation of the Th17/Treg balance [23], and STAT3 deficiency impairs RORγt expression, giving rise to the increased expression of FOXP3 [29]. Therefore, dysregulation of STAT3 results in the development of various inflammatory diseases, and loss of STAT3 in naive CD4<sup>+</sup> T cells inhibits the development of CNS inflammatory diseases [30, 31]. Several studies have introduced STAT3 as a risk factor allele for MS disease susceptibility [32–34]. These observations persuaded us to investigate whether the hypo- or hyper-methylation of STAT3 in CD4<sup>+</sup> T cells is associated with the susceptibility of MS.

In this study, we display that in CD4<sup>+</sup> T cells, STAT3 methylation decreases in relapsing–remitting MS (RRMS), whereas the gene expression of STAT3 increases.

**Main text**

**Methods**

**Study groups**

A total of 50 MS patients (36 males and 14 females) aged between 19 and 65 years with clinically RRMS were

collected from the Imam Reza Hospital of Tabriz University of Medical Sciences, East Azerbaijan Province, Iran. All the patients had RRMS according to the McDonald’s diagnostic criteria and were in the remission clinical phase. Disease remission was defined as improvement from baseline clinical status for at least three months. The cases were weekly being treated with interferon beta. Normal controls enrolled in this study were composed of 50 age, gender, and ethnically matched healthy subjects without any clinical or laboratory signs of autoimmune or inflammatory diseases. A written informed consent was obtained from each case, and the study protocol was approved by the Ethics Committee of the Tabriz University of Medical Sciences. The clinical/pathological data of both RRMS and controls are summarized in Table 1.

**Blood sampling and cell isolation**

Peripheral blood samples (20 ml) were obtained from all the patients with RRMS. After the blood collection, peripheral blood mononuclear cells were isolated using Ficoll-Paque™ plus gradient centrifugation (Biosera, UK) within 12 h. The isolation of CD4<sup>+</sup> T cells from peripheral blood mononuclear cells was carried out with the Miltenyi Biotech’s MACS System. The CD4<sup>+</sup> MACS Isolation Kit was applied to positively select CD4<sup>+</sup> T cells. The purity of the CD4<sup>+</sup> T cells was assessed with flow cytometry and assigned to be greater than 90%.

**DNA extraction and methylation-specific quantitative polymerase chain reaction (MS-qPCR)**

Total DNA isolated from the CD4<sup>+</sup> T cells was gathered in EDTA-containing tubes by the salting-out method. STAT3 promoter sequences and data were obtained from the NCBI (National Center for Biotechnology Information) database. STAT3 expression primers were designed by the aid of the PrimerQuest Tool, and the methylation- and demethylation (DM)-specific primers for STAT3 were designed using MethPrimer online database and OLIGO software. The primer sequences and product size for STAT3 are shown in Table 2. The methylation status of STAT3 was analyzed by applying the MS-qPCR. Power

**Table 1 Clinical characteristics of RRMS and control subjects**

Characteristics	RRMS group (n = 50)	Control group (n = 50)
Age	35.08 (19–65)	33.01 (22–51)
Gender (female/male)	36/14	31/19
EDSS	1.75 ± 0.31	NA
Disease duration	4.9 ± 1.6 (2–15 years)	NA

Data are shown as mean ± SD or frequencies

NA non-applicable, EDSS expanded disability status scale

**Table 2 PCR primers, melting temperature, and product size**

Primers	Sequence	Melting temperature	Product Sizes (bp)
STAT3 MF	TATCGTTTTTTGTATTCGTTT GTAC	58.2	192
MR	CCTACTTTAAACTTCAATTC TACGTA	59.0	
UMF	TTGTTTTTTGTATTTGTTTGT ATGG	57.5	
UMR	CCTACTTTAAACTTCAATTC TACATA	57.5	190

SYBR Green reagent (Thermo Fisher Scientific, USA) was utilized for MS-qPCR. The DM rate of STAT3 was calculated by a previously described formula [35, 36] in which DM is the ratio of amplification efficiency of the methylated to unmethylated samples:

$$DM\% = 100/[1 + 2(Ct.TG - Ct.CG)].$$

**RNA isolation and reverse transcriptase (RT)-PCR**

Total RNA from the collected CD4<sup>+</sup> T cells was isolated using TRIzol Reagent (Life Technologies, USA) based on the manufacturer’s instructions. RNA was then reverse transcribed with the Prime Script™ RT reagent Kit (Takara, Japan) as per the protocol recommended by manufacturer. Subsequently, SYBR Green reagent (Thermo Fisher Scientific) was used for quantitative real-time (qRT-PCR). Pfaffl method [37] was applied to calculate the relative gene expression. PCR cycles included a holding cycle at 95 °C for 15 min and held at 80 °C before the addition of 1.25 units of Taq polymerase (Invitrogen, USA). The forward and reverse primers used for STAT3 expression were comprised of 5’-TGG AGCTGCGGCAGTTTCTG-3’ and 5’-CCGCATCTG GTCCAGCGCAG-3’, respectively [38]. For STAT3, the temperature condition was as follows: 30 cycles of 95 °C for 1 min, 63 °C for 1 min, followed by one cycle of 72 °C for 5 min. The mRNA expression level was normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. STAT3 primer sequences are listed in Table 2.

**Statistical analysis**

Statistical analysis was performed with SPSS software version 25 (IBM Corp., Armonk, NY, USA). All the data were presented as mean ± standard error of mean (SEM). Kolmogorov–Smirnov test with P–P plot and Q–Q plot was employed for normal distributions. The differences

in the mRNA level of STAT3 between RRMS patient and control groups were evaluated by unpaired t-test. A P-value < 0.05 was considered as statistically significant difference.

**Results**

**STAT3 expression in the study groups**

Our results showed that the STAT3 expression level increased in patients in comparison with the control group (P-value < 0.0001; Fig. 1a).

**STAT3 methylation status in the study groups**


Methylation level (% M) of the promoter region of STAT3 was present in 23% (12/50) of MS cases, while this level was found in 62.9% (45/50) of the controls. The decrease level was statistically significant (P-value < 0.0001). In addition, a significant and strong negative correlation was found between the STAT3 gene methylation level and mRNA expression level for the methylation assay (Figs. 1b–e).

**Discussion**

FOXP3 is an essential transcription factor in the differentiation of Treg cells [40, 41]. Immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome are disorders found in patients with FOXP3 mutations [22, 40]. FOXP3-deficient mice also exhibit eosinophilia, hyperimmunoglobulinemia E syndrome, and dysregulated production of Th1 and Th2 cytokines [42]. These observations verifies the major role of FOXP3 in Treg development, control immune tolerance, and homeostasis [15]. The CD28 costimulatory molecule is another factor required for the Treg development and peripheral conversion. Th17 cells have immunopathogenic potential, and their responses have been associated with the murine models of collagen-induced arthritis and experimental autoimmune encephalitis.

STAT3 is one of the regulating factors in the reciprocal development of Th17 cells and Tregs. A previous study has been shown that STAT3 is directly involved in the FOXP3 expression and Treg development [27]. In the present study, we observed STAT3 hypomethylation in RRMS patients and found that the STAT3 gene expression increases in RRMS patients, but not in the control subjects.

The results of the STAT3 methylation level and gene expression status in our study demonstrated the decreased level of methylation and the increased mean of mRNA expression in the patient group compared to the healthy one (hypomethylated). Therefore, our findings reveal a critical novel epigenetic event and new insights into the pathogenesis of MS disease.



**Fig. 1** The gene expression and promoter methylation level of the STAT3 gene in MS and control groups. **a** STAT3 gene expression in patients compared with control subjects. Mean fold change in MS patients and control group was  $1.000 \pm 0.024$  and  $0.250 \pm 0.014$ , respectively (P-value < 0.0001). **b** The methylation level (% M) of STAT3 in MS patients compared with control group. The red dots are individual values, and boxes are the mean methylation for patient ( $30.56 \pm 1.317$ ) and control groups ( $59.08 \pm 1.986$ ). **c, d** Correlation analysis between methylation status and gene expression level of STAT3 in patients ( $R^2 = 0.8967$ , P-value < 0.0001, regression analysis) and control ( $R^2 = 0.9256$ , P-value < 0.0001, regression analysis) group. **e** Negative and positive controls for methylation assays. 5-Azacytidine and DNA sample treated with SssI methyltransferase were used as negative and positive controls, respectively [39]. (\*P-value < 0.05, \*\*P-value < 0.01, \*\*\*P-value < 0.001, \*\*\*\*P-value < 0.0001).

Regulation of the STAT3 in the present study maybe a novel promising treatment for MS as it has formerly been demonstrated that highly activated Th17 activity is related to STAT3 mutations [43]. Moreover, germline mutations in STAT3 causes the lymphoproliferation and early-onset autoimmunity [44]. An earlier investigation has reflected that STAT3-targeted therapeutics prevents experimental autoimmune uveitis mediated by Th17 cells [45]. STAT3 inhibitors are also effective in CNS autoimmune diseases [46].

Taken together, these findings affirm the role of STAT3 in Th17-mediated immune diseases. However, further studies are needed to fully elucidate the exact role of STAT3 in MS disease. STAT3 induction in the autoimmune therapy protocol is recommended.

### Limitations

The major concern of this study is the examination of STAT3 methylation on limited MS patients. The test of methylation on samples from various regions and in large areas in the country is suggested.

### Abbreviations

Treg: Regulatory T; STAT3: Signal transducer and activator of transcription 3; MS: Multiple sclerosis; CNS: Central nervous system; FOXP3: Forkhead box P3; Th17: T helper 17; IL: Interleukin; RRMS: Relapsing–remitting multiple sclerosis; NCBI: National Center for Biotechnology Information; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; SD: Standard deviation; DM: Demethylation; RT: Reverse transcriptase; qRT: Quantitative reverse transcriptase; SEM: Standard error of mean.

### Acknowledgements

This project was provided by the Student Research Committee for Scientific Research, Tabriz University of Medical Sciences, Tabriz, Iran No. 62387.

### Authors' contributions

Conceived and designed the experiments: conceptualization; AH, BB, ZB, and HA. Data curation; AH, SR, SN. Formal analysis; AH, TG, FM, and DS. Investigation; methodology; project administration; AH, VH. Software; NS, MA. Supervision; BB. Roles/writing—original draft; Writing: AH. Review & editing: AH, ZB, TG, NS, FM, VH, HA, MA, SR, SN, DS, and BB. All authors read and approved the final manuscript.

### Funding

This study has been supported and financed by the Student Research Committee for Scientific Research (No. 41090), Tabriz University of Medical Sciences, Tabriz, Iran to AH. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Ethics approval and consent to participate

A written informed consent was obtained from each case, and the study protocol was approved by the Ethics Committee of the Tabriz University of Medical Sciences.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup> Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. <sup>2</sup> Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. <sup>3</sup> Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. <sup>4</sup> Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. <sup>5</sup> Department of Neurology, Tabriz University of Medical Sciences, Tabriz, Iran. <sup>6</sup> Department of Basic Science, Faculty of Medicine, Maragheh University of Medical Sciences, Maragheh, Iran.

Received: 28 October 2020 Accepted: 19 December 2020

Published online: 29 December 2020

### References

- Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. *Cold Spring Harb Perspect Med*. 2018. <https://doi.org/10.1101/cshperspect.a028928>.
- Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: From mechanism to autoimmune therapy. *Int Immunopharmacol*. 2020;80:106221. <https://doi.org/10.1016/j.intimp.2020.106221>.
- Kaskow BJ, Baecher-Allan C. Effector T Cells in Multiple Sclerosis. *Cold Spring Harb Perspect Med*. 2018. <https://doi.org/10.1101/cshperspect.a029025>.
- Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. *Annu Rev Immunol*. 2004;22:531–62.
- Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. *Cold Spring Harb Perspect Biol*. 2012. <https://doi.org/10.1101/cshperspect.a006957>.
- Bhandoola A, Tai X, Eckhaus M, Auchincloss H, Mason K, Rubin SA, et al. Peripheral expression of self-MHC-II influences the reactivity and self-tolerance of mature CD4(+) T cells: evidence from a lymphopenic T cell model. *Immunity*. 2002;17(4):425–36. [https://doi.org/10.1016/s1074-7613\(02\)00417-x](https://doi.org/10.1016/s1074-7613(02)00417-x).
- Piccirillo CA, Thornton AM. Cornerstone of peripheral tolerance: naturally occurring CD4+ CD25+ regulatory T cells. *Trends Immunol*. 2004;25(7):374–80.
- Schildknecht A, Brauer S, Brenner C, Lahl K, Schild H, Sparwasser T, et al. FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T-cell tolerance induced by steady-state dendritic cells. *Proc Natl Acad Sci*. 2010;107(1):199–203.
- Ziegler SF, Buckner JH. FOXP3 and the regulation of Treg/Th17 differentiation. *Microbes Infect*. 2009;11(5):594–8. <https://doi.org/10.1016/j.micinf.2009.04.002>.
- Rudensky AY. Regulatory T cells and Foxp3. *Immunol Rev*. 2011;241(1):260–8. <https://doi.org/10.1111/j.1600-065X.2011.01018.x>.
- Zhang X, Izikson L, Liu L, Weiner HL. Activation of CD25+ CD4+ regulatory T cells by oral antigen administration. *J Immunol*. 2001;167(8):4245–53.
- Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinon N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med*. 2003;198(12):1875–86. <https://doi.org/10.1084/jem.20030152>.
- Liang S, Alard P, Zhao Y, Parnell S, Clark SL, Kosiewicz MM. Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. *J Exp Med*. 2005;201(1):127–37.
- Taams LS, Vukmanovic-Stejić M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ, et al. Antigen-specific T cell suppression by human CD4+ CD25+ regulatory T cells. *Eur J Immunol*. 2002;32(6):1621–30.
- Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. *Immunity*. 2000;12(4):431–40.
- Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+ CD25+ regulatory T cells. *J Immunol*. 2003;171(7):3348–52.



17. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. *Immunol Rev.* 2006;212(1):203–16.
18. Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. *Nat Immunol.* 2005;6(2):152–62. <https://doi.org/10.1038/nri1160>.
19. Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, et al. Regulatory T cells in patients with systemic lupus erythematosus. *J Autoimmun.* 2006;27(2):110–8. <https://doi.org/10.1016/j.jaut.2006.06.005>.
20. Haas J, Fritzsching B, Trübswetter P, Korporal M, Milkova L, Fritz B, et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. *J Immunol.* 2007;179(2):1322–30.
21. Mai J, Wang H, Yang XF. T helper 17 cells interplay with CD4+ CD25high-Foxp3+ Tregs in regulation of inflammations and autoimmune diseases. *Front Biosci.* 2010;15:986.
22. Hosseini A, Dolati S, Hashemi V, Abdollahpour-Alitappeh M, Yousefi M. Regulatory T and T helper 17 cells: their roles in preeclampsia. *J Cell Physiol.* 2018;233(9):6561–73.
23. Jhun J, Lee J, Byun J-K, Kim E-K, Woo J-W, Lee J-H, et al. Red ginseng extract ameliorates autoimmune arthritis via regulation of STAT3 pathway, Th17/Treg balance, and osteoclastogenesis in mice and human. *Mediat Inflamm.* 2014. <https://doi.org/10.1155/2014/351856>.
24. Traugott U, Lebon P. Multiple sclerosis: involvement of interferons in lesion pathogenesis. *Ann Neurol.* 1988;24(2):243–51. <https://doi.org/10.1002/ana.410240211>.
25. Hofstetter H, Gold R, Hartung HP. Th17 cells in MS and experimental autoimmune encephalomyelitis. *Int MS J.* 2009;16(1):12–8.
26. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. *Annu Rev Immunol.* 2009;27:485–517. <https://doi.org/10.1146/annurev.immunol.021908.132710>.
27. Pallandre J-R, Brillard E, Créange G, Radlovic A, Remy-Martin J-P, Saas P, et al. Role of STAT3 in CD4+ CD25+ FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. *J Immunol.* 2007;179(11):7593–604.
28. Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z, Baradaran B. Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune diseases. *J Cell Physiol.* 2020;239(9):5903–24.
29. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. *J Biol Chem.* 2007;282(13):9358–63.
30. Liu X, Lee YS, Yu C-R, Egwuagu CE. Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. *J Immunol.* 2008;180(9):6070–6.
31. Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. *Cytokine.* 2009;47(3):149–56. <https://doi.org/10.1016/j.cyto.2009.07.003>.
32. Cenit M, Alcina A, Márquez A, Mendoza JL, Díaz-Rubio M, de Las HV, et al. STAT3 locus in inflammatory bowel disease and multiple sclerosis susceptibility. *Genes.* 2010;11(3):264–8.
33. Jakkula E, Leppä V, Sulonen A-M, Varilo T, Kallio S, Kempainen A, et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. *Am J Hum Genet.* 2010;86(2):285–91.
34. Lill CM, Schjiede B-MM, Akkad DA, Blaschke P, Winkelmann A, Gerdes L-A, et al. Independent replication of STAT3 association with multiple sclerosis risk in a large German case–control sample. *Neurogenetics.* 2012;13(1):83–6.
35. Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M, et al. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. *J Urol.* 2007;177(5):1753–8.
36. Zhuo C, Li Z, Xu Y, Wang Y, Li Q, Peng J, et al. Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival. *Mol Cancer.* 2014;13(1):153.
37. Pfaffl MW. Quantification strategies in real-time polymerase chain reaction. Norfolk: Caister Academic Press; 2012.
38. Wang Y-C, Zheng L-H, Ma B-A, Zhou Y, Zhang M-H, Zhang D-Z, et al. Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma. *Acta Histochem.* 2011;113(4):402–8.
39. Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. *Blood J Am Soc Hematol.* 2010;115(6):1214–25.
40. Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. *J Autoimmun.* 2005;25(Suppl):56–62. <https://doi.org/10.1016/j.jaut.2005.04.008>.
41. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, et al. Foxp3-dependent programme of regulatory T-cell differentiation. *Nature.* 2007;445(7129):771–5.
42. Lin W, Truong N, Grossman WJ, Haribhai D, Williams CB, Wang J, et al. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. *J Allergy.* 2005;116(5):1106–15.
43. Wienke J, Janssen W, Scholman R, Spits H, van Gijn M, Boes M, et al. A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation. *Oncotarget.* 2015;6(24):20037–42. <https://doi.org/10.18632/oncotarget.5042>.
44. Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. *Blood.* 2015;125(4):591–9. <https://doi.org/10.1182/blood-2014-09-602763>.
45. Yu C-R, Lee YS, Mahdi RM, Surendran N, Egwuagu CE. Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. *PLoS ONE.* 2012;7(1):e29742.
46. Egwuagu CE, Larkin IJ. Therapeutic targeting of STAT pathways in CNS autoimmune diseases. *JAKSTAT.* 2013;2(1):e24134. <https://doi.org/10.4161/jkst.24134>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

